Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo

Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
May 26, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gainTreatment well tolerated and safe with no adverse effectsEnrollment into Phase...